DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.
Liu A, Zhang S, Wang M, Zhang L, Xu S, Nasimian A, Li S, Zhao S, Cao X, Tian J, Yu Y, Fan Z, Xiao K, Zhao H, Kazi JU, Ma L, Sun J.
Liu A, et al. Among authors: sun j.
Mol Carcinog. 2024 Jan;63(1):75-93. doi: 10.1002/mc.23637. Epub 2023 Sep 22.
Mol Carcinog. 2024.
PMID: 37737519